Merck Toll-Free Screening, Advice Service Planned For OTC Mevacor
Executive Summary
Merck would support an OTC version of its statin drug Mevacor with a customer education program that would ensure proper usage of the cholesterol-lowering medication, the firm said July 13 at a joint meeting of FDA's Nonprescription and Endocrinologic & Metabolic Drugs Advisory Committees.
You may also be interested in...
Bristol OTC Pravachol Study Enrollment Does Not Match Indication - FDA
Bristol-Myers Squibb may need to better demonstrate consumers' ability to make self-selection choices based on appropriate cholesterol levels in order to convince FDA that an OTC version of Pravachol is approvable.
Mevacor Study Comparing Rx And OTC Use Is Among FDA Panel Suggestions
Merck should conduct a head-to-head comparison study of Mevacor in prescription and over-the-counter settings, Endocrinologic and Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for Mevacor.
Mevacor Study Comparing Rx And OTC Use Is Among FDA Panel Suggestions
Merck should conduct a head-to-head comparison study of Mevacor in prescription and over-the-counter settings, Endocrinologic and Metabolic Drugs Advisory Committee member William Tamborlane, MD, said during a review of Merck's OTC switch application for Mevacor.